Synexus benefits from clinical trials growth in Hungary
Upward trend is set to continue
Synexus, a clinical trials specialist headquartered in Chorley, Lancashire, UK, says it increased its clinical trials activity in Hungary by 25% during the first half of 2010. The company has been operating a Dedicated Research Centre in the country since 2006, which has become one of its most successful CEE sites.
The Budapest-based operation has been involved in more than 74 trials since being acquired by Synexus.
Dr Erika Nemeth, Synexus’ country manager in Hungary, believes that this growth trend for clinical trials in Hungary will continue: ‘The high standards of medical and research and development expertise in Hungary have resulted in high levels of participation in clinical trials and mean that pharma and biotech companies remain keen to include Hungary in their global clinical trial programmes. There are no signs that this trend is set to decline.’
The prevalence of chronic conditions such as CVD and COPD among the Hungarian population, together with little preventative healthcare and healthcare education provision means there is substantial scope for clinical trials. Forecasts also predict that the pharmaceutical market in Hungary will increase significantly in the coming decade, encouraging the major players to establish a stronger and more proactive presence here before their new drugs come to market.
Michael Fort, chief executive of Synexus, said the productivity of investigators, the attractive overhead costs and the medical expertise and innovation in Hungary make it one of the company’s key areas for future development.
